Zacks Research Weighs in on Novartis AG’s Q2 2025 Earnings (NYSE:NVS)

Novartis AG (NYSE:NVS) – Equities researchers at Zacks Research increased their Q2 2025 earnings per share (EPS) estimates for shares of Novartis in a report released on Monday, September 2nd. Zacks Research analyst E. Bagri now expects that the company will post earnings per share of $2.07 for the quarter, up from their prior forecast of $2.06. The consensus estimate for Novartis’ current full-year earnings is $7.48 per share. Zacks Research also issued estimates for Novartis’ Q1 2026 earnings at $2.03 EPS.

NVS has been the subject of several other research reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Novartis in a report on Friday, July 19th. Jefferies Financial Group cut Novartis from a “buy” rating to a “hold” rating in a report on Tuesday. Barclays raised Novartis to a “strong sell” rating in a report on Monday, June 24th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $121.00 price target (up from $119.00) on shares of Novartis in a report on Thursday. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $118.38.

Novartis Stock Performance

NVS opened at $116.70 on Thursday. The company has a current ratio of 0.93, a quick ratio of 0.72 and a debt-to-equity ratio of 0.47. Novartis has a 12-month low of $92.19 and a 12-month high of $120.92. The firm has a 50 day moving average of $112.66 and a two-hundred day moving average of $104.51. The firm has a market capitalization of $238.53 billion, a PE ratio of 15.75, a P/E/G ratio of 1.77 and a beta of 0.57.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Thursday, July 18th. The company reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.10. The firm had revenue of $12.87 billion during the quarter, compared to analysts’ expectations of $12.24 billion. Novartis had a return on equity of 34.56% and a net margin of 33.76%. During the same period last year, the business posted $1.83 earnings per share.

Institutional Trading of Novartis

A number of institutional investors and hedge funds have recently made changes to their positions in NVS. Raymond James & Associates increased its holdings in Novartis by 1.3% in the 2nd quarter. Raymond James & Associates now owns 536,607 shares of the company’s stock worth $57,127,000 after acquiring an additional 6,767 shares in the last quarter. Manning & Napier Advisors LLC acquired a new position in shares of Novartis during the 2nd quarter worth about $15,044,000. O Shaughnessy Asset Management LLC raised its position in shares of Novartis by 6.5% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 180,764 shares of the company’s stock worth $17,485,000 after purchasing an additional 11,080 shares during the last quarter. TD Asset Management Inc lifted its stake in Novartis by 314.8% in the 4th quarter. TD Asset Management Inc now owns 55,096 shares of the company’s stock valued at $5,563,000 after buying an additional 41,815 shares in the last quarter. Finally, FORA Capital LLC acquired a new stake in Novartis in the 1st quarter worth about $2,968,000. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.